Monitor for future announcements on clinical trial initiation or additional manufacturing scale-up orders, which could signal growing commercial potential and provide upside to Lifecore’s CDMO revenue pipeline.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $7.02entry
- T+1 · 9mo ago −0.85%α +0.46% · $6.96
- T+5 · 8mo ago −5.84%α −3.60% · $6.61
- T+20 · 8mo ago −45.30%α −41.51% · $3.84
- T+60 · 6mo ago −30.91%α −42.21% · $4.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid drug candidate for at-home treatment of inflammatory acne using Indomo's ClearPen™ self-injection device. This expands their existing collaboration and supports Indomo's planned Phase 2 clinical trials in 2026, highlighting Lifecore's growing role in autoinjector-based therapeutics beyond its traditional ophthalmic focus.
Key Facts
- Lifecore will produce engineering and clinical batches of DT-001 for Indomo’s acne treatment program.
- This is the second agreement between Lifecore and Indomo, expanding prior formulation and process optimization work.
- The drug candidate DT-001 is designed for use with Indomo’s investigational ClearPen™ intradermal self-injection device.
- Indomo aims to advance into Phase 2 clinical trials in 2026; the product is not yet FDA-approved.
- Acne affects 50 million Americans annually, but only 1 million receive corticosteroid injections due to limited dermatologist access.
Financial Impact
No financial terms disclosed; likely modest near-term revenue contribution from development services
Risk Factors
- Indomo’s program depends on successful Phase 2 trial outcomes and regulatory approval, which are uncertain.
- No disclosed financial value limits visibility into revenue impact for Lifecore.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249719 |
Track record
20 reports on LFCR
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
- Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
- Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
- Nov 4, 202612d ago 8-K Bearish 6/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
- Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
- Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers